American journal of translational research · 2023
Changes in the IL-18, IL-22, and T lymphocyte subset levels in patients with hepatitis B-related liver cirrhosis and their predictive values for hepatorenal syndrome.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Ligong, Qiao Qinghua, Hou Linhu
Аннотация
OBJECTIVE: To investigate the changes in the interleukin (IL)-18, IL-22, and T lymphocyte subset levels in patients with hepatitis B-related liver cirrhosis and to determine their predictive values for hepatorenal syndrome (HRS).
METHODS: Clinical data of 70 healthy individuals (group A) and 84 patients with hepatitis B-related liver cirrhosis (group B) admitted to Hospital 989 of the PLA Joint Logistics Support Force were retrospectively collected. The serum levels of IL-18 and IL-22, concentrations of cluster of differentiation (CD)3+, CD4+, and CD8+ cells, as well as the CD4+/CD8+ ratio in the peripheral blood T lymphocyte subsets were measured. Further, their predictive values for HRS were determined. Logistic regression analysis was employed to identify independent risk factors for HRS.
RESULTS: In group B, the posttreatment IL-18 and IL-22 levels and CD8+ cell concentration significantly decreased after treatment, whereas the CD3+ and CD4+ cell concentrations and CD4+/CD8+ ratio increased. Notably, the serum IL-18 and IL-22 levels were higher in patients with HRS than in those without. Also, the CD3+ and CD4+ cell concentrations and CD4+/CD8+ ratio in the peripheral blood were lower in patients with HRS than in those without. The sensitivities of the serum IL-18 and IL-22 levels for predicting HRS were 90.32% and 80.65%, and the specificities were 71.70% and 77.36%, respectively. The sensitivities of CD3+, CD4+, and CD8+ cell concentrations for predicting HRS were 77.42%, 90.32%, and 83.87%, and the specificity was 67.92%, 64.15%, and 52.83%, respectively. Moreover, the sensitivity and specificity of CD4+/CD8+ ratio for predicting HRS were 80.65% and 86.79%, respectively.
CONCLUSIONS: IL-18, IL-22, and T lymphocyte subset levels may have significant implications in the progression of hepatitis B-related liver cirrhosis, and detecting these markers could aid in treatment, evaluation, and prediction of HRS in patients. Furthermore, IL-18 and IL-22 levels and the CD4+/CD8+ ratio were identified as independent risk factors for HRS.
METHODS: Clinical data of 70 healthy individuals (group A) and 84 patients with hepatitis B-related liver cirrhosis (group B) admitted to Hospital 989 of the PLA Joint Logistics Support Force were retrospectively collected. The serum levels of IL-18 and IL-22, concentrations of cluster of differentiation (CD)3+, CD4+, and CD8+ cells, as well as the CD4+/CD8+ ratio in the peripheral blood T lymphocyte subsets were measured. Further, their predictive values for HRS were determined. Logistic regression analysis was employed to identify independent risk factors for HRS.
RESULTS: In group B, the posttreatment IL-18 and IL-22 levels and CD8+ cell concentration significantly decreased after treatment, whereas the CD3+ and CD4+ cell concentrations and CD4+/CD8+ ratio increased. Notably, the serum IL-18 and IL-22 levels were higher in patients with HRS than in those without. Also, the CD3+ and CD4+ cell concentrations and CD4+/CD8+ ratio in the peripheral blood were lower in patients with HRS than in those without. The sensitivities of the serum IL-18 and IL-22 levels for predicting HRS were 90.32% and 80.65%, and the specificities were 71.70% and 77.36%, respectively. The sensitivities of CD3+, CD4+, and CD8+ cell concentrations for predicting HRS were 77.42%, 90.32%, and 83.87%, and the specificity was 67.92%, 64.15%, and 52.83%, respectively. Moreover, the sensitivity and specificity of CD4+/CD8+ ratio for predicting HRS were 80.65% and 86.79%, respectively.
CONCLUSIONS: IL-18, IL-22, and T lymphocyte subset levels may have significant implications in the progression of hepatitis B-related liver cirrhosis, and detecting these markers could aid in treatment, evaluation, and prediction of HRS in patients. Furthermore, IL-18 and IL-22 levels and the CD4+/CD8+ ratio were identified as independent risk factors for HRS.